FDA Advisory Committee supports the use of Novartis inhalation powder, Tobramycin
The FDA Advisory Committee voted 13 to 1 that research showed adequate evidence to support the use of tobramycin inhalation powder by cystic fibrosis patients whose lungs contain the bacteria Pseudomonas aeruginosa, the leading cause of lung function loss in patients with CF. Tobramycin inhalation...